Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
INDP | US
-0.04
-2.63%
Healthcare
Biotechnology
30/06/2024
21/10/2024
1.47
1.44
1.47
1.41
Indaptus Therapeutics Inc. a clinical biotechnology company develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma hepatocellular colorectal and pancreatic tumors as well as chronic hepatitis B virus and human immunodeficiency virus infection which is in Phase 2 clinical trial. The company was formerly known as Intec Parent Inc. and changed its name to Indaptus Therapeutics Inc. in August 2021. Indaptus Therapeutics Inc. is headquartered in New York New York.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
98.7%1 month
126.9%3 months
86.1%6 months
82.9%-
-
2.50
0.02
0.02
1.03
-
-
-16.48M
14.99M
14.99M
-
-
-
-
-127.04
1.54
0.45
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.47
Range1M
0.54
Range3M
1.35
Rel. volume
0.15
Price X volume
6.17K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| LYRA THERAPEUTICS INC | LYRA | Biotechnology | 0.244 | 15.97M | 0.16% | n/a | 118.63% |
| Apollomics Inc. Class A Ordinary Shares | APLM | Biotechnology | 0.1368 | 15.04M | 6.79% | n/a | 21.43% |
| Cingulate Inc. Common Stock | CING | Biotechnology | 4.92 | 14.98M | 7.19% | n/a | 10.72% |
| ImmunoPrecise Antibodies Ltd | IPA | Biotechnology | 0.5352 | 14.94M | -0.89% | n/a | 49.00% |
| Cara Therapeutics Inc | CARA | Biotechnology | 0.2656 | 14.57M | 0.19% | n/a | 406.66% |
| Evogene Ltd | EVGN | Biotechnology | 2.58 | 14.44M | 7.50% | n/a | 26.41% |
| IMNN | IMNN | Biotechnology | 0.9925 | 14.29M | 0.71% | n/a | 37.13% |
| Evaxion Biotech A/S | EVAX | Biotechnology | 2.54 | 14.17M | -3.79% | n/a | 837.11% |
| Cyclacel Pharmaceuticals Inc | CYCCP | Biotechnology | 7.3 | 13.88M | 0.00% | n/a | 0.50% |
| Tenax Therapeutics Inc | TENX | Biotechnology | 4.05 | 13.81M | 2.53% | n/a | 3.14% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5263 | 7.69M | -2.17% | 0.03 | 16.03% |
| Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.4659 | 4.44M | -2.96% | n/a | 19.98% |
| Forza X1 Inc | FRZA | Recreational Vehicles | 0.19 | 2.99M | -13.68% | n/a | 0.97% |
| EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.06 | 2.71M | 0.00% | n/a | 17.32% |
| Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 3.65 | 2.01M | -6.89% | n/a | 0.00% |
| Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.011 | 1.01M | 10.00% | n/a | -37.05% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 1.03 | - | Expensive |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 2.50 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 86.05 | - | Par |
| Debt to Equity | 0.02 | -1.23 | Expensive |
| Debt to Assets | 0.02 | 0.25 | Cheaper |
| Market Cap | 14.99M | - | Emerging |